Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels

Abstract 

Atorvastatin and rosuvastatin at maximal doses are both highly effective in lowering low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels. Rosuvastatin has been shown to be more effective than atorvastatin in lowering LDL-C, small dense LDL-C and in raising high-density lipoprotein (HDL) and its subclasses. Intestinal lipoproteins containing apolipoprotein (apo) B-48 are also thought to be atherogenic particles. Our purpose in this study was to compare the effects of daily oral doses of atorvastatin 80mg/day and rosuvastatin 40mg/day over a 6-week period on serum apo B-48 (a marker of intestinal lipoproteins) and remnant lipoprotein cholesterol (RemL-C) levels (a marker of partially metabolized lipoproteins of both intestinal and liver origin), using novel direct assays in 270 hyperlipidemic men and women. Both atorvastatin and rosuvastatin caused significant (p<0.0001) and similar median decreases in TG (−33.0%, −27.6%), RemL-C (−58.7%, −61.5%), and apoB-48 (−37.5%, −32.1%) as compared to baseline. Our findings utilizing a specific immunoassay and a fairly large number of subjects extend prior studies indicating that statins significantly lower apolipoprotein B containing lipoproteins of both intestinal and liver origin.

Abbreviations: TC, total cholesterol, TG, triglyceride, HDL-C, high density lipoprotein cholesterol, TC/HDL-C ratio, total cholesterol/HDL cholesterol ratio, LDL, low density lipoprotein, TC/HDL-C ratio, total cholesterol/HDL cholesterol ratio, RemL-C, remnant lipoprotein cholesterol, apo B-48, apolipoprotein, DM, diabetes mellitus, CHD, coronary heart disease

Keywords: Statins, Lipoproteins, Apolipoprotein B-48 and remnant lipoprotein cholesterol